Date Title
11/23/2011 Want you kids to listent to you? Talk to them about their future goals
  Less than a quarter of parents help children determine future goals more>
11/4/2011 ATTN: Health, News and Lifestyle Editors
  Albertans with Colorectal Cancer Get a New Sense of Hope more>
8/11/2011 Studies Published in The New England Journal of Medicine Highlight Potential New Option in the Treatment of Bone Loss
  Twice-Yearly Administration of Denosumab Resulted in 68 Per cent Reduction in Risk for a Vertebral Fracture and 40 Per cent Reduction in Risk for a Hip Fracture in Women with Postmenopausal Osteoporosis more>
7/22/2011 OSTEOPOROSIS CANADA APPLAUDS ALBERTA, SASKATCHEWAN & NOVA SCOTIA GOVERNMENTS FOR LISTING DENOSUMAB, BUT URGES ALL TO PROVIDE BROADER ACCESS
  July 25, 2011 – Toronto – This month, the governments of Alberta, Saskatchewan and Nova Scotia have taken a very progressive step by adding denosumab (Prolia®) to their provincial drug plans. more>
6/8/2011 Health Canada Approves Amgen's Xgeva™ (Denosumab)
  First targeted bone therapy offers new option for patients with bone metastases from breast, prostate, non-small cell lung cancer and other solid tumours more>
4/4/2011 MANY CANADIAN WOMEN WITH OSTEOPOROSIS AND AT RISK FOR FRACTURE RESTRICTED FROM ACCESS TO A NEW TREATMENT OPTION THAT PREVENTS BROKEN BONES
  TORONTO, April 4 /CNW/ - On April 4, 2011, the Canadian Expert Drug Advisory Committee (CEDAC) through the Common Drug Review (CDR) recommended that provincial drug plans approve funding for Prolia® (denosumab), more>
2/1/2011 ALL CANADIAN WOMEN AT INCREASED RISK OF BROKEN BONES ONE STEP CLOSER TO HAVING ACCESS TO A NEW TREATMENT OPTION
  QUEBEC SHOWS LEADERSHIP IN SUPPORTING PEOPLE WITH OSTEOPOROSIS more>
2/1/2011 WOMEN IN QUEBEC NOW HAVE ACCESS TO PROLIA® (DENOSUMAB)
  Quebec is the first province to make Prolia available to patients through both public and private drug plans more>
11/9/2010 Canadian Teens Don't Think Science is 'Cool'
  Science and technology-based careers may have exploded in recent years, but Canada's youth have more>
11/8/2010 PUBLISHED RESULTS SHOW DENOSUMAB SUPERIOR TO ZOMETA® IN DELAYING OR PREVENTING BONE COMPLICATIONS IN PATIENTS WITH BONE METASTASES FROM ADVANCED BREAST CANCER
  Bone is one of the most common sites for distant metastases affecting up to 75 per cent of patients with advanced breast cancer more>
9/8/2010 PROLIATM (denosumab) APPROVED BY HEALTH CANADA FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS AT HIGH RISK FOR FRACTURE
  First and only RANK Ligand inhibitor offers physicians and patients a new choice in osteoporosis therapy more>
9/8/2010 Prolia Approved by Health Canada
  Amgen Canada today announced that Health Canada has approved Prolia™ (denosumab) more>
6/5/2010 NEW ANALYSES OF DENOSUMAB PIVOTAL PHASE 3 TRIALS REINFORCE POTENTIAL ADVANTAGES OVER STANDARD OF CARE
  Integrated Analysis Shows Denosumab Superiority over Zometa® In Delaying or Preventing Skeletal Related Events in Broad Population with Advanced Cancer more>
6/5/2010 DENOSUMAB DEMONSTRATED SUPERIORITY OVER ZOMETA® IN DELAY OF COMPLICATIONS DUE TO BONE METASTASES IN ADVANCED PROSTATE CANCER
  The Third of Three Pivotal Head-To-Head Trials Submitted To FDA for Treatment of Patients with Bone Metastases more>
5/6/2010 Amgen Canada Holds Hands With Local Community
  Amgen Canada, today announced the local programs selected to receive support through its new community philanthropy initiative, Holding Hands, at an employee launch celebration more>
11/19/2009 Call For Applications: The Amgen Award for Science Teaching Excellence (AASTE)
  Amgen today announced that applications for the 19th Annual Amgen Award for Science and Teaching Excellence (AASTE) are now being accepted more>
8/11/2009 Studies published in the New England Journal of Medicine highlight potential new option in the treatment of bone loss
  Amgen today announced the publication of results from two pivotal Phase 3 studies investigating the safety and effectiveness of denosumab at reducing fracture risk in more than 7,800 women with postmenopausal osteoporosis more>
6/23/2009 Health Canada issues Notice of Compliance (NOC) for the first and only platelet producer indicated for the treatment of immune (idiopathic) thrombocytopenic purpura (ITP)
  Amgen Canada announced today that Health Canada has issued a Notice of Compliance (NOC) for NplateTM (romiplostim) more>
6/17/2009 2009 Recipients Recognized in Communities Across Canada
  Today, Amgen announced the four Canadian science teachers who are this year’s recipients of the Amgen Award for Science Teaching Excellence (AASTE) more>
12/3/2008 Ontario Takes a Bold Step Towards Personalized Medicine
  First province to reimburse new, innovative therapy for Colorectal Cancer more>
11/1/2008 Amgen offers $10,000 teaching award
  Amgen expands award for science teaching excellence to (AASTE) to recognize outstanding teachers in four provinces more>
6/10/2008 Amgen celebrates new corporate office
  Amgen Canada celebrated its grand opening today and announced the first Ontario recipient of the Amgen Award for Science Teaching Excellence (AASTE) at a special ceremony presided by local dignitaries and leaders in the Mississauga business community more>
5/15/2008 Health Canada approves 'personalized medicine' for metastatic colorectal cancer
  The first and only treatment of its kind in Canada for metatstatic colorectal cancer has received conditional* approval from Health Canada. VectibixTM (panitumumab) represents an important new option for colorectal cancer patients whose disease has more>
5/15/2008 HEALTH CANADA APPROVES ‘PERSONALIZED MEDICINE’
  Albertans with Colorectal Cancer Get a New Sense of Hope more>
5/13/2008 Amgen Canada honours outstanding educator in British Columbia
  Amgen Canada is delighted to recognize Gregg Mitchell, of Timberline Secondary School, as the winner of the 2008 Amgen Award for Science Teaching Excellence (AASTE) as result of his outstanding ability to inspire students and produce results in science education. more>